Navigation Links
Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug

BARCELONA, Spain | March 08, 2007 | The Business Intelligence firm La Merie S.L. reported today that Sanofi-Aventis’ first-in-class CB1 antagonist Acomplia (rimonabant) has at least five competitors in clinical stages up to phase III and many more in earlier phases of R&D. While Acomplia received EU approval in June 2006, the FDA requested more time to review the file. Acomplia is indicated for the treatment of patients with obesity or overweight plus cardiometabolic risk factors and achieved EU sales of € 31 mln in its first months in selected markets. However, some countries such as Germany consider Acomplia as a non-reimbursable life-style drug. Sanofi-Aventis is undertaking a huge clinical program to profile Acomplia in additional populations such as in type 2 diabetes (1st line), insulinized patients, dyslipidemia or atherosclerosis. Another field of potential use of CB1 antagonists lies in neuroscience, such as addiction and cognitive disorders. These results and more were found in a search conducted by La Merie Business Intelligence. The competitor analysis of CB1 antagonists can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.

Rimonabant has been studied in more than 6,000 patients. Results of the RIO-LIPIDS study showed that a one-year treatment of overweight and obese patients with abnormal lipid levels with once daily rimonabant significantly reduced body weigth by an average of 6.9 kg in comparison to a loss of 1.5 kg in the placebo group. More importantly, it improved a range of cardiometabolic risk factors that may contribute to type 2 diabetes and heart disease. Results of a two-year treatment with rimonabant in the RIO-
'"/>




Page: 1 2 3

Related medicine technology :

1. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
2. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
3. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
4. New Data Confirm That Use of Levemir Can Limit Weight Gain
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Choosing Lab Quality Management Software
7. Optimizing Quality Control Data Management
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
10. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
11. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
Post Your Comments:
(Date:9/30/2014)...  Tasly Pharmaceuticals, Inc., the world,s leader in ... the launch of Deepure. Deepure is ... and women concerned with supporting their overall health ... while helping keep their health care cost down.  ... formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Pro-Memory ...
(Date:9/30/2014)... 2014 Aileron Therapeutics, Inc. - Product ... Markets Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline ... Aileron Therapeutics, Inc.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... Orally Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF ... products division of a wholly owned subsidiary of Par ... provides an update on two of its pipeline products. ... 7, 2009, Strativa submitted a New Drug Application (NDA) ...
... April 8 Phase III data, published online this ... Metabolism , showed that arzoxifene, an investigational selective estrogen ... Company (NYSE: LLY ), significantly increased lumbar ... postmenopausal women with normal or low bone mass, versus ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- There,s no ... prevent type 2 diabetes, a new study says. ... vitamin D might protect people against type 2 diabetes, ... deficiency and the blood sugar disease. In this ... and vitamin D by focusing on genes that control ...
(Date:9/30/2014)... to cut climate-changing carbon emissions will reduce other ... benefits, according to a new study released today. ... options included in the final Clean Power Plan, ... premature deaths and hospitalizations, and hundreds of heart ... the new study, Health Co-benefits of Carbon Standards ...
(Date:9/30/2014)... cancer is the leading cause of cancer death in ... so many medical professionals encourage women to get mammograms, ... a minority of suspicious mammograms actually leads to a ... worry for women and their familiesnot to mention the ... and biopsies. , Recently, a different type of ...
(Date:9/30/2014)... Utah (PRWEB) September 30, 2014 A new ... Ohio State University studied the impact of stress on metabolism ... burger and french fries from a fast food restaurant, about ... woman’s resting metabolism for 20 minutes every hour for 7 ... Results showed that women who had experienced a stressful event ...
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:'Virtual breast' could improve cancer detection 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:UCI study uncovers important process for immune system development 2
... ... Ovid, part of Wolters Kluwer Health and a global leader in ... medical, scientific and academic markets, will be showcasing recent enhancements to ... of a new psychology lexicon, based on the American Psychological Association,s ...
... , The Patient Safety Authority Encourages Older Persons ... Tips Based Upon Authority Data , HARRISBURG, Pa., ... occur in those 65 and older, including residents in nursing ... Authority,s 2009 December Patient Safety Advisory . , According ...
... age are more likely to engage in risky health behaviors ... aging process may act as a disincentive to behave ,sensibly, ... in anticipation of ,miserable, old age. These findings 1 ... Queen,s University Belfast, Northern Ireland, are published online in Springer,s ...
... tied to academic achievement, study finds , TUESDAY, Dec.1 ... adulthood may boost brainpower, making for better school grades ... suggests. , Given that most doctors and laypeople know ... impact on healthy bodies, the authors of a new ...
... , RANCHO SANTA FE, Calif., Dec. 1 ... grapes acclaimed for its potential to forestall the ravages ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091201/NY18305 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20091111/NY08935LOGO ... ResVez, Inc. of Rancho Santa Fe, Calif. contains as ...
... , , ... At ECPA,s Food Supply Forum, Experts Agree That Adapting Food,Production ... Prof. John Beddington, Chief Scientific Adviser to ... on science and have a,sound evidence basis. "Having a chief ...
Cached Medicine News:Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Binge drinking youths find getting old a drag 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3Health News:First Resveratrol Nutrition Bar Hits the Market 2Health News:Food Security to be the Top Issue for EU's Science Chief 2
... The Guidant Flextend lead ... pace/sense lead with an ... extendable/retractable helix design offers ... for permanent implantation in ...
... a low profile implantable bipolar fixed ... of either the atrium or the ... with a screwdriver shape stylet which ... The ring tip and fixation screw ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector....
Medicine Products: